At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Pedro Barata, Director of Clinical Genitourinary Medical Oncology Research Program at University Hospitals Seidman Cancer Center, delivered a talk on “Treatment Sequencing After IO/TKI Progression”.
Dr. Barata emphasized that treatment attrition in refractory renal cell carcinoma (RCC) is a real challenge, as nearly half of patients are lost with each subsequent line of therapy. He argued against holding back effective options for later, highlighting the importance of using the best therapies early when appropriate.
He reviewed data supporting the activity of cabozantinib, tivozanib, and lenvatinib-based regimens in patients progressing after IO/TKI combinations, while also noting the emerging role of belzutifan and other HIF-2α inhibitors. However, he cautioned that rechallenging with immunotherapy has shown limited benefit so far, stressing the need for ongoing trials exploring novel strategies and combinations in the refractory setting.
Join us in this conversation.